ROCKET PHARMACEUTICALS, INC. — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 71/100
What the filing says
Rocket Pharmaceuticals entered into a Loan and Security Agreement dated September 30, 2026, with Hercules Capital, Inc. as agent and lender, for up to $150,000,000 in aggregate Term Loan Advances across five tranches. The facility is secured by substantially all company assets and is structured to support development of RP-A501 for Danon Disease, with tranche availability contingent on regulatory milestones including an FDA approval milestone for a Biologics License Application.
Why this rating
At $150M against $212.5M market cap, this represents ~71% of company value—transformational liquidity for a clinical-stage biotech. Materially extends runway and de-risks near-term operations, but carries substantial obligations and restrictive covenants.
Tradability signal
NO TRADE
No trade: positive news with only -2.1% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.03% over 4 hrs, n=201). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $2.51 ▲ 2.95% | at our read · unknown $2.44 | +10 min · unknown $2.47 ▲ 1.23% | +30 min · unknown $2.52 ▲ 3.28% | +1 hr · unknown $2.57 ▲ 5.33% | +4 hrs · unknown $2.56 ▲ 5.12% |
The stock had already moved -2.87% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.